P135 (0160) BRENTUXIMAB-VEDOTIN + BENDAMUSTINE: A HIGHLY EFFECTIVE SALVAGE TREATMENT UN REFRACTORY/RELAPSED PATIENTS WITH HODGKIN LYMPHOMA

P135 (0160) BRENTUXIMAB-VEDOTIN + BENDAMUSTINE: A HIGHLY EFFECTIVE SALVAGE TREATMENT UN REFRACTORY/RELAPSED PATIENTS WITH HODGKIN LYMPHOMA

Bibliographic Details
Format:	Article
Language:	English
Published:	Wiley 2018-10-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000547978.61156.2d

Similar Items

P139 (0169) BRENTUXIMAB VEDOTIN ALONE AND IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY FOR PRIMARY REFRACTORY OR RELAPSED HODGKIN LYMPHOMA: MULTICENTRE EXPERIENCE OF THE POLISH LYMPHOMA RESEARCH GROUP
Published: (2018-10-01)

TARGETED THERAPY WITH BRENTUXIMAB VEDOTIN IN RELAPSED AND REFRACTORY FORMS OF CLASSICAL HODGKIN LYMPHOMA
by: E. A. Demina
Published: (2017-11-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
by: Swetha Kambhampati, et al.
Published: (2022-10-01)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
by: Matthew Mei, et al.
Published: (2022-10-01)

Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma
by: Patrick Greve, et al.
Published: (2023-07-01)

P017 (0120) IMMUNOLOGIC BIOMARKERS OF RESPONSE AND RESISTANCE TO BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Published: (2018-10-01)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
by: Fulvio Massaro, et al.
Published: (2022-02-01)

Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
by: Jozef Michalka, et al.
Published: (2022-10-01)

Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01)

P115 (0048) BRENTUXIMAB VEDOTIN (BV) AS MAINTENANCE OR SALVAGE THERAPY AFTER ASCT FOR RELAPSED/REFRACTORY (R/R) HL
Published: (2018-10-01)

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors
by: Ruizhi Zhao, et al.
Published: (2024-03-01)

P110 (0014) SUCCESSFUL TREATMENT OF HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN RELAPSING AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Published: (2018-10-01)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
by: Hannah Moatti, et al.
Published: (2022-10-01)

Potentials of brentuximab vedotin in the treatment of relapse/refractory cutaneous T-cell lymphomas: literature review and authors’ observation
by: L. G. Gorenkova, et al.
Published: (2019-07-01)

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting
by: Eyre, T, et al.
Published: (2017)

Brentuximab vedotin resistance in classic Hodgkin's lymphoma and its therapeutic strategies: a review
by: Dayeeta Bera, et al.
Published: (2024-02-01)

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin
by: Adrian Schmidt
Published: (2020-11-01)

Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis
by: Aimee Schad, et al.
Published: (2023-09-01)

P113 (0040) PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN FIRST REFRACTORY/RELAPSED CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) BEFORE AUTOLOGOUS TRANSPLANTATION
Published: (2018-10-01)

Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report
by: Federica Giannotti, et al.
Published: (2024-03-01)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
by: Anna Sureda-Balari, et al.
Published: (2022-10-01)

P119 (0078) REAL LIFE DATA OF BRENTUXIMAB VEDOTIN USE IN RELAPSED/REFRACTORY HL IN SWEDEN
Published: (2018-10-01)

P120 (0086) OUTCOMES AND TOXICITIES AFTER BRENTUXIMAB VEDOTIN (BV) MAINTENANCE IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENT EXPOSED TO BV PRIOR TO AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT
Published: (2018-10-01)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
by: Julia Driessen, et al.
Published: (2022-10-01)

Assessment of the efficiency of Brentuximab Vedotin in patients with pulmonary Hodgkin Lymphoma by the mean of neutrophil to lymphocyte ratio
by: Gokhan Erdem, et al.
Published: (2018-04-01)

Brentuximab vedotin in children and adolescents with Hodgkin’s lymphoma and anaplastic large cell lymphoma – literature review and own experience
by: N. V. Myakova, et al.
Published: (2016-03-01)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
by: Harsh Shah, et al.
Published: (2022-10-01)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: D. Ermann, et al.
Published: (2022-06-01)

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY
by: M. S. Dal, et al.
Published: (2022-06-01)

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
by: Randall C. Dere, et al.
Published: (2023-03-01)

P122 (0090) BRENTUXIMAB VEDOTIN PRIOR TO ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMAS REDUCES CHRONIC GVHD WITHOUT WORSENING THE OUTCOME
Published: (2018-10-01)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
by: Jennifer E. Agrusa, et al.
Published: (2023-05-01)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
by: Susan Y. Wu, MD, et al.
Published: (2023-11-01)

T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
by: Sharon M. Castellino, et al.
Published: (2022-10-01)

P1083: BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY
by: R. Garcia-Sanz, et al.
Published: (2022-06-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)